The Week In... Pharma (03-07/02)
  • Posted on: 07/02/2020
  • Category: Industry

The Week In... Pharma (03-07/02)

UK government issues statement on trade cooperation with EU, Dutch biotech sector feels benefits of EMA relocation, pharmacists are ‘embracing’ online channels and NICE looks again at Novartis’s migraine drug after initial rejection.

Interested in Star’s innovative outsourcing and resourcing solutions?

Contact Operations Director, Mark Ward, on 07872 105 540 or email mark.ward@starmedical.co.uk.

On the hunt for a new role, or just curious?

Visit our candidate page, submit your CV to candidates@starmedical.co.uk, or give our offices a ring!

Statement from UK government on EU trade, including pharma industry

A written statement from the UK government has highlighted the importance of trade co-operation with the EU, including for pharmaceuticals.

Dutch biotech sector feel benefits of EMA move, says industry leader

The Netherlands’ biotech sector has already seen an upswing following the relocation of the European Medicines Agency (EMA) to Amsterdam following Brexit, according to an influential figure in the sector.

UK government pledges £20m to CEPI for coronavirus vaccine research

The UK Health Secretary announced the government will give Coalition for Epidemic Preparedness Innovations (CEPI) £20 million to research vaccines for the 2019 novel coronavirus (2019-nCoV).

Pharmacists ‘embracing online channels’ for wider reach

A new survey published by Medicspot has revealed that pharmacists are embracing online channels to reach a wider audience – but online dispensing is still seen as a threat.

After rejection, NICE agrees to look again at migraine drug Aimovig

The UK’s medicines cost-effectiveness agency NICE has agreed to look again at its decision to turn down NHS funding of Novartis’ Aimovig for migraine prevention after an appeal.

While you’re here…

…and are interested in our content, why not sign up to our newsletter?

 It’s just below.